Targeted therapy in head and neck cancer

Current Opinion in Otolaryngology and Head and Neck Surgery

Volumn 19, Issue 2, 2011, Pages 132-137

  Licitra, Lisa ^a   Bergamini, Cristiana ^a   Mirabile, Aurora ^a   Granata, Roberta ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

biological update; clinical update; head neck cancer; target therapy

Indexed keywords

AFATINIB; BEVACIZUMAB; CARBOPLATIN; CETUXIMAB; CISPLATIN; CIXUTUMUMAB; CURCUMIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; EVEROLIMUS; FIGITUMUMAB; FLUOROURACIL; GEFITINIB; LAPATINIB; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; METHOTREXATE; MONOCLONAL ANTIBODY; NIMOTUMUMAB; NIMOTUZUMAB; PACLITAXEL; PANITUMUMAB; PEMETREXED; PF 299804; PHOSPHATIDYLINOSITOL 3 KINASE; SORAFENIB; UNCLASSIFIED DRUG; ZALUTUMUMAB;

BLEEDING; CANCER RADIOTHERAPY; CANCER SURVIVAL; CANCER THERAPY; CHEMOPROPHYLAXIS; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; DYSPHAGIA; HEAD AND NECK CANCER; HUMAN; HYPOPHARYNX CANCER; LARYNX CANCER; MAINTENANCE THERAPY; METASTASIS; MOLECULARLY TARGETED THERAPY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NONHUMAN; OROPHARYNX CANCER; OROPHARYNX TUMOR; PAIN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHYSICIAN; PRIORITY JOURNAL; RASH; REVIEW; UNSPECIFIED SIDE EFFECT; WART VIRUS;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; CLINICAL TRIALS, PHASE III AS TOPIC; COMBINED MODALITY THERAPY; DRUG DELIVERY SYSTEMS; DRUGS, INVESTIGATIONAL; HUMANS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; OTORHINOLARYNGOLOGIC NEOPLASMS; RADIOTHERAPY, ADJUVANT; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 79953863840     PISSN: 10689508     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOO.0b013e328344b668     Document Type: Review

References (60)

1. Wilting SM, Smeets SJ, Snijders PJ. Genomic profiling identifies common HPV-associated chromosomal alterations in squamous cell carcinomas of cervix and head and neck. BMC Med Genomics 2009; 2:32.
2. Chung CH, Parker JS, Karaca G, et al. Molecular classification of head and neck squamous cell carcinomas using patterns of gene expression. Cancer Cell 2004; 5:489-500. (Pubitemid 38610250)
3. Chung CH, Parker JS, Ely K, et al. Gene expression profiles identify epithelial-to-mesenchymal transition and activation of nuclear factor-kB signalling as characteristic of a high risk squamous cell carcinoma. Cancer Res 2006; 66:8210-8218. (Pubitemid 44299189)
4. Pramana J, Van den Brekel MW, van Velthuysen ML, et al. Gene expression profiling to predict outcome after chemoradiation in head and neck cancer. Int J Radiat Oncol Biol Phys 2007; 69:1544-1552. (Pubitemid 350116428)
5. de Jong MC, Pramana J, Knegjens JL, et al. HPV and high-risk gene expression profiles predict response to chemoradiotherapy in head and neck cancer, independent of clinical factors. Radiother Oncol 2010; 95:365-370. Genomic analysis in the clinical setting.
6. Pomerantz RG, Grandis JR. The role of epidermal growth factor receptor in head and neck squamous cell carcinoma. Curr Oncol Rep 2003; 5:140-146. (Pubitemid 38898776)
7. Grandis JR, Sok JC. Signaling through the epidermal growth factor receptor during the development of malignancy. Pharmacol Ther 2004; 102:37-46. (Pubitemid 38429984)
8. Ang KK, Berkey BA, Tu X, et al. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res 2002; 62:7350-7356. (Pubitemid 36025259)
9. Eriksen JG, Steiniche T, Askaa J, et al. The prognostic value of epidermal growth factor receptor is related to tumor differentiation and the overall treatment time of radiotherapy in squamous cell carcinomas of the head and neck. Int J Radiat Oncol Biol Phys 2004; 58:561-566. (Pubitemid 38142484)
10. Bentzen SM, Atasoy BM, Daley FM, et al. Epidermal growth factor receptor expression in pretreatment biopsies from head and neck squamous cell carcinoma as a predictive factor for a benefit from accelerated radiation therapy in a randomized controlled trial. J Clin Oncol 2005; 23:5560-5567.
11. Freier K, Joos S, Flechtenmacher C, et al. Tissue microarray analysis reveals site-specific prevalence of oncogene amplifications in head and neck squamous cell carcinoma. Cancer Res 2003; 63:1179-1182. (Pubitemid 36348691)
12. Mrhalova M, Plzak J, Betka J, Kodet R. Epidermal growth factor receptor: its expression and copy numbers of EGFR gene in patients with head and neck squamous cell carcinomas. Neoplasma 2005; 52:338-343. (Pubitemid 41076203)
13. Gebhart E, Ries J, Wiltfang J, et al. Genomic gain of the epidermal growth factor receptor harboring band 7p12 is part of a complex pattern of genomic imbalances in oral squamous cell carcinomas. Arch Med Res 2004; 35:385-394. (Pubitemid 40018178)
14. Chung CH, Ely K, McGavran L, et al. Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas. J Clin Oncol 2006; 24:4170-4176. (Pubitemid 46622295)
15. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 2010; 11:21-28. Update of phase III study on the role of cetuximab.
16. Vermorken J, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008; 11:1116-1127.
17. Bonner JA, Harari PM, Giralt J, et al. EGFR expression and clinical outcome in head and neck patients treated with radiotherapy with or without cetuximab. J Clin Oncol ASCO Annual Meeting Proc 2006; 24:282S.
18. Babu KG, Viswanath L, Reddy BK, et al. An open-label, randomized, study of h-R3mAb (nimotuzumab) in patients with advanced (stage III or IVa) squamous cell carcinoma of head and neck (SCCHN): four-year survival results from a phase IIb study [abstract]. J Clin Oncol 2010; 28:15s (Suppl.):5530.
19. Ferris RL, Kotsakis AP, Heron DE, et al. A phase II trial of postoperative radiotherapy (RT), cisplatin, and panitumumab in patients with high-risk, resected locally advanced squamous cell carcinoma of the head and neck (SCCHN) [abstract]. J Clin Oncol 2010; 28:15s (Suppl.):TPS262.
20. Gupta M, Madholia V, Gupta N, et al. Results from a pilot study of nimotuzumab with concurrent chemoradiation in patients with locally advanced squamous cell carcinoma of head and neck [abstract]. J Clin Oncol 2010; 28:15s (Suppl.):5565.
21. Pfister DG, Su YB, Kraus DH, et al. Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: a pilot phase II study of a new combined-modality paradigm. J Clin Oncol 2006; 24:1072-1078. (Pubitemid 46638804)
22. Langer CJ, Lee JW, Patel UA, et al. Preliminary analysis of ECOG 3303: concurrent radiation (RT), cisplatin (DDP) and cetuximab (C) in unresectable, locally advanced (LA) squamous cell carcinoma of the head and neck (SCCHN) [abstract]. J Clin Oncol 2008; 26 (Suppl.):6006.
23. Dietz A, Flentje M, Hagen R, et al. Docetaxel, cisplatin (TP), and radiation with or without cetuximab in advanced larynx carcinoma (DeLOS II trial) [abstract]. J Clin Oncol 2010; 28:15s (Suppl.):TPS265.
24. Haddad RI, Tishler RB, Norris C, et al. Phase I study of C-TPF in patients with locally advanced squamous cell carcinoma of the head and neck. J Clin Oncol 2009; 27:4448-4453.
25. Mesia R, Rueda A, Vera R, et al. Is there a role for adjuvant cetuximab after radiotherapy (RT) plus cetuximab in patients (pts) with locally advanced squamous cell carcinoma of the oropharynx? A phase II randomized trial [abstract]. J Clin Oncol 2010; 28 (Suppl):5534.
26. Wanebo HJ, Ghebremichael MS, Burtness B, et al. Phase II induction cetuximab (C225), paclitaxel (P), and carboplatin (C) followed by chemoradiation with C225, P, C, and RT 68-72Gy for stage III/IV head and neck squamous cancer: primary site organ preservation and disease control at 2 years (ECOG, E2303) [abstract]. J Clin Oncol 2010; 28:15s (Suppl.):5513.
27. Kuhnt T, Sandner A, Wendt T, et al. Phase I trial of dose-escalated cisplatin with concomitant cetuximab and hyperfractionated-accelerated radiotherapy in locally advanced squamous cell carcinoma of the head and neck. Ann Oncol 2010; 21:2284-2289.
28. Wirth LJ, Allen AM, Posner MR, et al. Phase I dose-finding study of paclitaxel with panitumumab, carboplatin and intensity-modulated radiotherapy in patients with locally advanced squamous cell cancer of the head and neck. Ann Oncol 2010; 21:342-347.
29. Lefebvre J, Pointreau Y, Rolland F, et al. Sequential chemoradiotherapy (SCRT) for larynx preservation (LP): preliminary results of the randomized phase II TREMPLIN study [abstract]. J Clin Oncol 2009; 27:15s (Suppl.):6010.
30. Hayes DN, Raez LE, Sharma AK, et al. Multicenter randomized phase II trial of combined radiotherapy and cisplatin with or without erlotinib in patients with locally advanced squamous cell carcinoma of the head and neck (SCCAHN): preliminary toxicity results [abstract]. J Clin Oncol 2010; 28:15s (Suppl.):5580.
31. Cohen EE, Davis DW, Karrison TG, et al. Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study. Lancet Oncol 2009; 10:247-257.
32. HarringtonKJ, BerrierA,RobinsonM, et al. Phase II study of oral lapatinib, a dualtyrosine kinase inhibitor, combined with chemoradiotherapy (CRT) in patients (pts) with locally advanced, unresected squamous cell carcinoma of the head and neck (SCCHN) [abstract]. J Clin Oncol 2010; 28:15s (Suppl.):5505.
33. Arias de la Vega F, Herruzo I, de las Heras M, et al. A phase I/II study of erlotinib in combination with chemoradiation in patients with surgically resected locally advanced squamous head and neck cancer (HNSCC) [abstract]. J Clin Oncol 2010; 28:15s (Suppl.):TPS266.
34. Specenier PM, Lalami Y, Vermorken J, et al. EORTC 24051: unexpected side effects of a phase I study of TPF induction chemotherapy (IC) followed by chemoradiation (CRT) with lapatinib (LAP), a dual EGFR/ErbB2 inhibitor, in patients with locally advanced larynx and hypopharynx squamous cell carcinoma (LA-LxHxSCC) [abstract]. J Clin Oncol 2009; 27:15s (Suppl.):6017.
35. Seiwert TY, Haraf DJ, Cohen EE, et al. A phase I study of bevacizumab (B) with fluorouracil (F) and hydroxyurea (H) with concomitant radiotherapy (X) (B-FHX) for poor prognosis head and neck cancer (HNC). J Clin Oncol ASCO Annual Meeting Proc 2006; 24:287s.
36. Kotsakis AP, Heron DE, Kubicek GJ, et al. Phase II randomized trial of radiotherapy (RT), cetuximab (E), and pemetrexed (Pem) with or without bevacizumab (B) in locally advanced squamous cell carcinoma of the head and neck (SCCHN) [abstract]. J Clin Oncol 2010; 28:15s (Suppl.):TPS264.
37. Pfister DG, Lee NY, Sherman E, et al. Phase II study of bevacizumab (B) plus cisplatin (C) plus intensity-modulated radiation therapy (IMRT) for locoregionally advanced head and neck squamous cell cancer (HNSCC): preliminary results [abstract]. J Clin Oncol 2009; 27:15s (Suppl.):6013.
38. Meluch AA, Spigel D, Burris HA, et al. Combined modality therapy with radiation therapy (RT), chemotherapy, bevacizumab, and erlotinib in the treatment of patients (pts) with locally advanced squamous carcinoma of the head and neck [abstract]. J Clin Oncol 2009; 27:15s (Suppl.):6012.
39. Milas L, Fang FM, Mason KA, et al. Importance of maintenance therapy in C225-induced enhancement of tumor control by fractionated radiation. Int J Radiat Oncol Biol Phys 2007; 67:568-572.
40. Milas L, Hittelman WN. Cancer stem cells and tumor response to therapy: current problemsand future prospects.Semin RadiatOncol2009; 19:96-105. Hypothesis on tumor biology.
41. Mesia R, Rueda A, Vera R, et al. Is there a role for adjuvant cetuximab after radiotherapy (RT) plus cetuximab in patients (pts) with locally advanced squamous cell carcinoma of the oropharynx? A phase II randomized trial [abstract]. J Clin Oncol 2010; 28:15s (Suppl.):5534.
42. Reported by Dr Schrijvers - 2nd International Conference on Innovative Approaches in Head and Neck Oncology Meeting report, Publishing Working Group ESMO - www.esmo.org.
43. Cohen EE, Haraf DJ, Kunnavakkam R. Epidermal growth factor receptor inhibitor gefitinib added to chemoradiotherapy in locally advanced head and neck cancer. J Clin Oncol 2010; 28:3336-3343.
44. Burtness B, Goldwasser MA, Flood W, et al. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol 2005; 23:8646-8654. (Pubitemid 46211507)
45. Baselga J, Trigo JM, Bourhis J, et al. Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinumrefractory metastatic and/or recurrent squamous cell carcinoma of the head and neck. J Clin Oncol 2005; 23:5568-5577.
46. Herbst RS, Arquette M, Shin DM, et al. Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck. J Clin Oncol 2005; 23:5578-5587.
47. Trigo J, Hitt R, Koralewski P, et al. Cetuximab monotherapy is active in patients (pts) with platinum-refractory recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN): results of a phase II study. J Clin Oncol ASCO Annual Meeting Proc 2004; 22:488s.
48. Mesía R, Rivera F, Kawecki A, et al. Quality of life of patients receiving platinum-based chemotherapy plus cetuximab first line for recurrent and/or metastatic squamous cell carcinoma of the head and neck. Ann Oncol 2010; 21:1967-1973.
49. Licitra L, Mesia R, Rivera F, et al. Evaluation of EGFR gene copy number as a predictive biomarker for the efficacy of cetuximab in combination with chemotherapy in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck: EXTREME study. Ann Oncol 2010. [Epub ahead of print]
50. Vermorken JB, Stohlmacher J, Davidenko I, et al., Primary efficacy and safety results of SPECTRUM, a phase 3 trial in patients (pts) with recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN) receiving chemotherapy with or without panitumumab (pmab). ESMO 2010.
51. Machiels JH, Subramanian S, Ruzsa A, et al. An open-label, randomized, phase III trial of zalutumumab, a human monoclonal EGF receptor (EGFr) antibody, versus best supportive care, in patients with noncurable squamous cell carcinoma (SCCHN) of the head and neck who have failed standard platinum-based chemotherapy (ZALUTE) [abstract]. J Clin Oncol 2010; 28:18s (Suppl.):LBA5506.
52. Stewart JS, Cohen EE, Licitra L, et al. Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck. J Clin Oncol 2009; 27:1864-1871.
53. Soulieres D, Senzer NN, Vokes EE, et al. Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol 2004; 22:77-85. (Pubitemid 41095117)
54. Abidoye OO, Cohen EE, Wong SJ, et al. A phase II study of lapatinib (GW572016) in recurrent/metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN). J Clin Oncol 2006; 24 (Suppl):5568.
55. Seiwert TY, Clement PM, Cupissol D, et al. BIBW 2992 versus cetuximab in patients with metastatic or recurrent head and neck cancer (SCCHN) after failure of platinum-containing therapy with a cross-over period for progressing patients: preliminary results of a randomized, open-label phase II study. J Clin Oncol 2010; 28 (Suppl):5501.
56. Argiris A, Ghebremichael M, Gilbert J, et al. A phase III randomized, placebo-controlled trial of docetaxel (D) with or without gefitinib (G) in recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): a trial of the Eastern Cooperative Oncology Group (ECOG) [abstract]. J Clin Oncol 2009; 27:15s (Suppl.):6011.
57. Le Tourneau C, Winquist E, Hotte SJ, et al. Phase II trial of the irreversible oral pan-HER inhibitor PF-00299804 (PF) as first-line treatment in recurrent and/ or metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN) [abstract]. J Clin Oncol 2010; 28:15s (Suppl.):5531.
58. Elser C, Siu LL, Winquist E, et al. Phase II trial of sorafenib in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or nasopharyngeal carcinoma. J Clin Oncol 2007; 25:3766-3773. (Pubitemid 47372619)
59. Sabichi AL, Kies MS, Glisson BS, et al. A phase II study of sorafenib in combination with carboplatin and paclitaxel in patients with metastatic or recurrent squamous cell cancer of the head and neck (SCCHN) [abstract]. J Clin Oncol 2010; 28:15s (Suppl.):5532.
60. Schmitz S, Kaminsky-Forrett M, Henry S, et al. Phase II study of figitumumab in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: GORTEC 2008-02. J Clin Oncol 2010; 28 (Suppl):5500.